Orchestra BioMed Holdings financials
$6.08+3.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.0K | $110.0K | $30.9M | $861.0K | $836.0K | $868.0K | $253.0K | $987.0K | $778.0K | $620.0K | $262.0K | $419.0K |
| Gross profit | $63.0K | $78.0K | $30.9M | $812.0K | $790.0K | $824.0K | $195.0K | $919.0K | $734.0K | $586.0K | $215.0K | $378.0K |
| Gross margin | 71.6% | 70.9% | 99.8% | 94.3% | 94.5% | 94.9% | 77.1% | 93.1% | 94.3% | 94.5% | 82.1% | 90.2% |
| Operating income | -$22.4M | -$22.1M | $6.8M | -$20.3M | -$19.3M | -$18.9M | -$16.7M | -$16.3M | -$16.9M | -$14.4M | -$12.5M | -$14.5M |
| Net income | -$24.1M | -$20.7M | $6.0M | -$20.8M | -$19.4M | -$18.8M | -$16.2M | -$15.4M | -$16.0M | -$13.5M | -$12.8M | -$13.3M |
| Net margin | −27362.5% | −18778.2% | 19.4% | −2419.0% | −2316.1% | −2160.7% | −6385.4% | −1562.9% | −2054.0% | −2171.5% | −4892.4% | −3178.0% |
| Diluted EPS | $-0.38 | $-0.33 | $0.10 | $-0.40 | $-0.50 | $-0.49 | $-0.42 | $-0.41 | $-0.45 | $-0.38 | $-0.36 | $-0.38 |
| EBITDA | -$22.3M | -$22.0M | $6.8M | -$20.2M | -$19.2M | -$18.8M | -$16.6M | -$16.3M | -$16.8M | -$14.3M | -$12.4M | -$14.5M |
| Operating cash flow | -$19.3M | -$22.2M | -$2.3M | -$14.6M | -$15.5M | -$16.6M | -$13.5M | -$13.7M | -$10.2M | -$13.1M | -$11.0M | -$10.3M |
| Free cash flow | -$19.6M | -$22.4M | -$2.3M | -$14.9M | -$15.6M | -$16.7M | -$13.6M | -$13.8M | -$10.3M | -$13.1M | -$11.0M | -$10.3M |
| Diluted shares | 63.8M | 62.7M | 62.2M | 52.2M | 38.4M | 38.2M | 38.1M | 37.6M | 35.8M | 35.8M | 35.4M | 35.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.5M | $28.4M | $34.7M | $42.0M | $18.7M | $18.3M |
| Short-term investments | $89.5M | $66.0M | $71.8M | $53.8M | $15.2M | $31.5M |
| Total debt | $34.8M | $14.3M | $14.3M | $14.2M | $14.4M | $14.3M |
| Total assets | $115.7M | $100.7M | $114.9M | $104.8M | $42.8M | $59.1M |
| Total liabilities | $86.3M | $49.7M | $51.5M | $61.1M | $42.5M | $42.2M |
| Shareholders' equity | $29.4M | $41.2M | $63.4M | $43.7M | $295.0K | $16.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology